[go: up one dir, main page]

MX2020006309A - Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. - Google Patents

Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.

Info

Publication number
MX2020006309A
MX2020006309A MX2020006309A MX2020006309A MX2020006309A MX 2020006309 A MX2020006309 A MX 2020006309A MX 2020006309 A MX2020006309 A MX 2020006309A MX 2020006309 A MX2020006309 A MX 2020006309A MX 2020006309 A MX2020006309 A MX 2020006309A
Authority
MX
Mexico
Prior art keywords
methods
isoxazoline parasiticide
patient
blepharitis
disclosed
Prior art date
Application number
MX2020006309A
Other languages
English (en)
Inventor
Joseph G Vehige
Douglas Michael Ackermann
Shawn D Hickok
Bobak Robert Azamian
Original Assignee
Tarsus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66814591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020006309(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tarsus Pharmaceuticals Inc filed Critical Tarsus Pharmaceuticals Inc
Publication of MX2020006309A publication Critical patent/MX2020006309A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente invención se describen métodos para tratar o prevenir afecciones oftálmicas y dermatológicas en un paciente, incluidas afecciones de la superficie ocular tales como blefaritis. Los métodos pueden incluir administrar directamente de forma tópica a la superficie ocular de uno o más ojos de un paciente que necesite tratamiento de una cantidad efectiva de un parasiticida de isoxazolina, parasiticida de formamidina u otros ingredientes activos, formulados en una composición oftálmica, la composición oftálmica además comprende un vehículo farmacéuticamente aceptable. También se describen las composiciones.
MX2020006309A 2017-12-15 2018-12-14 Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. MX2020006309A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762599213P 2017-12-15 2017-12-15
US201862615855P 2018-01-10 2018-01-10
US201862626612P 2018-02-05 2018-02-05
US201862689787P 2018-06-25 2018-06-25
US201862746498P 2018-10-16 2018-10-16
PCT/US2018/065849 WO2019118928A1 (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methods for treating blepharitis

Publications (1)

Publication Number Publication Date
MX2020006309A true MX2020006309A (es) 2021-01-29

Family

ID=66814591

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006309A MX2020006309A (es) 2017-12-15 2018-12-14 Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
MX2024000828A MX2024000828A (es) 2017-12-15 2020-07-13 Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024000828A MX2024000828A (es) 2017-12-15 2020-07-13 Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.

Country Status (19)

Country Link
US (14) US10835517B2 (es)
EP (2) EP3723739B1 (es)
JP (2) JP2021506971A (es)
KR (4) KR20250059552A (es)
CN (3) CN119174758A (es)
AU (3) AU2018385766B2 (es)
BR (1) BR112020012018A2 (es)
CA (1) CA3085787A1 (es)
DK (1) DK3723739T3 (es)
ES (1) ES2981130T3 (es)
FI (1) FI3723739T3 (es)
HU (1) HUE067461T2 (es)
IL (3) IL275339B2 (es)
MX (2) MX2020006309A (es)
PL (1) PL3723739T3 (es)
PT (1) PT3723739T (es)
SI (1) SI3723739T1 (es)
WO (1) WO2019118928A1 (es)
ZA (1) ZA202004155B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
SI3723739T1 (sl) * 2017-12-15 2024-08-30 Tarsus Pharmaceuticals, Inc. Paraziticidni pripravki na osnovi izoksazolina in njihova uporaba za zdravljenje blefaritisa
JP7569781B2 (ja) 2018-07-27 2024-10-18 アペルタ バイオサイエンシズ，エルエルシー デモデックスにより誘発される眼の異常および顔面の異常を治療するためのスピノシン配合
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
WO2020257663A1 (en) * 2019-06-19 2020-12-24 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
EP4511123A1 (en) * 2022-04-22 2025-02-26 Attillaps Holdings Inc. Anticholinergic agents and muscarinic agonists for the treatment of demodex related conditions
WO2024168149A1 (en) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
KR20250143845A (ko) * 2023-04-08 2025-10-02 성-잔 린 각막 손상의 치료 방법
WO2025034554A1 (en) * 2023-08-04 2025-02-13 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361974A (en) 1940-02-07 1944-11-07 John A Rietmann Electrolytic cell
US3781355A (en) 1969-12-12 1973-12-25 Boots Pure Drug Co Ltd Pesticidal compounds and compositions
US3864497A (en) 1970-12-01 1975-02-04 Boots Pure Drug Co Ltd Acaricidal and insecticidal 1,5-diphenyl-3-methyl-1,3,5-triazapenta-1,4-diener
JPS6033429Y2 (ja) 1975-09-30 1985-10-04 株式会社田村電機製作所 周波数切替機構
US4389397A (en) 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US5019392A (en) 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US5614545A (en) 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
US4957918A (en) 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
US6001822A (en) 1989-04-11 1999-12-14 Pfizer Inc. Antiparasitic formulations
FR2656526B1 (fr) 1990-01-02 1994-10-28 Virbac Sa Laboratoires Dispositif a liberation controlee et procede de preparation.
AU6021794A (en) 1993-01-11 1994-08-15 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5632999A (en) 1993-08-18 1997-05-27 Virbac, Inc. Sustained release pyriproxifen compositions for parasite control
US5981500A (en) 1994-01-12 1999-11-09 Pfizer Inc. Antiparasitic agents related to the milbemycins and avermectins
FR2729539B1 (fr) 1995-01-23 1997-04-11 Virbac Lab Dispositif a liberation controlee de substances chimiques, destine a etre fixe sur un animal et procede de preparation dudit dispositif
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
RU2126668C1 (ru) 1996-10-17 1999-02-27 Багров Сергей Николаевич Мазь для лечения блефаритов "демалон"
FR2761886B1 (fr) 1997-04-14 2000-05-05 Virbac Sa Compositions contenant au moins un polymere cationique et au moins une molecule active contenue dans au moins un vecteur micro ou nanoparticulaire, et leur utilisation pour le traitement de surfaces vivantes ou inertes
US5968990A (en) 1997-10-14 1999-10-19 Isp Investments Inc. Water-dilutable, microemulsion concentrate and pour-on formulations thereof
AU9799398A (en) 1997-10-14 1999-05-03 Isp Investments Inc. Stabilized concentrates of water unstable aza compounds and o/w miniemulsions thereof
DE69940227D1 (de) 1998-05-08 2009-02-12 Univ Miami Verwendung von sub-antimikrobiellen tetracyclinen zur Behandlung von okularer Rosacea
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
GB9825402D0 (en) 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
US7897559B2 (en) 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US6696067B2 (en) 2001-04-12 2004-02-24 Ondeo Nalco Company Cosmetic compositions containing dispersion polymers
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
CA2473760C (en) 2002-02-08 2008-11-04 Merck & Co., Inc. Topical ivermectin composition
US7906128B2 (en) 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
AU2004231323C1 (en) 2003-04-24 2016-11-03 Galderma Holding SA Topical formulation of ivermectin for the treatment of dermatological conditions
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US7531186B2 (en) 2003-12-17 2009-05-12 Merial Limited Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
CN102558082B (zh) 2004-03-05 2015-09-30 日产化学工业株式会社 异噁唑啉取代苯甲酰胺化合物的制备中间体
WO2005092329A1 (en) 2004-03-12 2005-10-06 Christian Diehl Topical and intravaginal microbicidal antiparasitic compositions comprising quassinoids or quassinoid-containing plant extracts
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
TWI350728B (en) 2004-10-08 2011-10-21 Wyeth Corp Amitraz compositions
US9186345B2 (en) 2004-10-12 2015-11-17 Hakon Hakonarson Method of treating skin diseases
GB2419093A (en) 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
AU2005304034B2 (en) 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
DE102004053964A1 (de) 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
WO2006119174A1 (en) * 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Method for treating ocular demodex
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
AU2006285613B2 (en) 2005-09-02 2011-11-17 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and harmful organism-controlling agent
FR2891460B1 (fr) 2005-09-30 2010-07-30 Galderma Sa Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
US20090143410A1 (en) 2005-12-14 2009-06-04 Kanu Maganbhai Patel Isoxazolines for Controlling Invertebrate Pests
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
AU2007240954A1 (en) 2006-04-20 2007-11-01 E. I. Du Pont De Nemours And Company Pyrazolines for controlling invertebrate pests
JP2008044880A (ja) 2006-08-15 2008-02-28 Bayer Cropscience Ag 殺虫性イソオキサゾリン類
JP5256753B2 (ja) 2007-03-29 2013-08-07 住友化学株式会社 イソオキサゾリン化合物とその有害生物防除用途
BRPI0810196A2 (pt) 2007-04-10 2011-12-06 Bayer Cropscience Ag inseticidas de derivados de aril isoxazolina
JP2010526112A (ja) * 2007-05-09 2010-07-29 ガニアル イミュノテラペウティクス インコーポレイテッド （ｓ，ｒ）−３−フェニル−４，５−ジヒドロ−５−イソオキサゾール酢酸−一酸化窒素ならびに抗癌剤および抗ウイルス剤としてのその使用
BRPI0809770B8 (pt) 2007-06-13 2022-12-06 Du Pont Composto e composição para controlar uma praga de invertebrados
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
KR20100075996A (ko) 2007-10-03 2010-07-05 이 아이 듀폰 디 네모아 앤드 캄파니 무척추 해충의 방제를 위한 나프탈렌 이속사졸린 화합물
FR2922108A1 (fr) 2007-10-11 2009-04-17 Virbac Sa Utilisation d'un derive de 1-n-(halo-3-pyridylmethyle)-n-methylamino-1-alkylamino -2- nitroethylene pour la preparation d'une composition pharmaceutique veterinaire pour lutter contre les puces
FR2925337B1 (fr) 2007-12-21 2010-01-15 Virbac Composition pharmaceutique contenant un derive de n-phenylpyrazole et du glycofurol, utilisation pour la preparation d'un medicament veterinaire topique pour lutter contre les puces
EP2285346A1 (en) 2008-03-26 2011-02-23 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin desease using tetracycline family antibiotics
US20090317503A1 (en) 2008-06-20 2009-12-24 Ocusoft, Inc. Eyelid Preparation and Method of Use
WO2010003923A1 (en) 2008-07-09 2010-01-14 Basf Se Pestcidal active mixtures comprising isoxazoline compounds i
US8389738B2 (en) 2008-07-09 2013-03-05 Nissan Chemical Industries, Ltd. Production method of isoxazoline-substituted benzoic acid amide compound
US9173728B2 (en) 2008-11-19 2015-11-03 Merial Inc. Multi-cavity container having offset indentures for dispensing fluids
KR101660068B1 (ko) 2008-11-19 2016-09-26 메리얼 인코포레이티드 기생충 감염 치료를 위한 1-아릴피라졸 단독 또는 포름아미딘과의 조합을 포함하는 조성물
BRPI0823302B1 (pt) 2008-12-16 2017-01-31 Virbac composição farmacêutica líquida que contém um derivado de n-fenilpirazol, e utilização para a preparação de um medicamento veterinário tópico para lutar contra pulgas
PL2379537T3 (pl) * 2008-12-19 2013-03-29 Elanco Tiergesundheit Ag Pochodne izooksazoliny i ich zastosowanie jako pestycydów
US8313752B2 (en) 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
FR2945797B1 (fr) 2009-05-20 2015-11-06 Virbac Sa Conditionnement alimentaire,pharmaceutique ou veterinaire de securite et son procede de fabrication
JP5246182B2 (ja) 2010-02-24 2013-07-24 ライオン株式会社 点眼剤、防腐剤及び防腐力向上剤
KR20130018739A (ko) 2010-03-03 2013-02-25 네오큐티스 에스아 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법
GB2480899B (en) 2010-04-12 2014-11-19 Exosect Ltd Control of arthropods in animal environments
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
CN102260252A (zh) * 2010-05-24 2011-11-30 盟科医药技术(上海)有限公司 可用于治疗细菌感染的新噁唑烷酮
RU2472505C2 (ru) 2010-12-07 2013-01-20 Общество с ограниченной ответственностью "Экохимтех" Лечебно-профилактический препарат на основе антималярийного средства и пробиотика
EP2654757A1 (en) * 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
KR102027723B1 (ko) 2010-12-27 2019-10-01 인터벳 인터내셔널 비.브이. 국소 적용 이속사졸린 제제
JP5952302B2 (ja) 2010-12-29 2016-07-13 ニチャミン、ルイス・ディー 眼の治療のための方法及びキット
JP2014505089A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー 無脊椎有害動物を防除するためのイソオキサゾリン誘導体
WO2012120399A1 (en) 2011-03-10 2012-09-13 Pfizer Inc. Spirocyclic isoxazoline derivatives as antiparasitic agents
EP2694048B1 (en) * 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments
RS61048B1 (sr) 2011-09-12 2020-12-31 Boehringer Ingelheim Animal Health Usa Inc Paraziticidne kompozicije koje sadrže izoksazolin aktivni agens, postupak i njihove primene
CN102552114A (zh) 2012-03-19 2012-07-11 段亚东 甲硝唑眼用凝胶及其制备方法和用途
US9345522B2 (en) 2012-05-22 2016-05-24 Matthew Songer Bone fixation screw and method
RS57284B1 (sr) 2012-08-31 2018-08-31 Zoetis Services Llc Kristalne forme 1-(5’-(5-(3,5-dihlor-4-fluorfenil)-5-(trifluormetil)-4,5-dihidroizoksazol-3-il)-3’h-spiro[azetidin-3,1’-izobenzofuran]-1-il)-2-(metilsulfonil)etanona
US9095566B1 (en) 2013-06-28 2015-08-04 Edward Quicksilver Yavitz Eyelash and eyelid margin infections
US9233118B2 (en) 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
WO2019126541A1 (en) 2017-12-20 2019-06-27 Attillaps Holdings Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
AU2014296454B2 (en) 2013-07-29 2018-06-21 Attillaps Holdings Organophosphates for treating afflictions of the skin
HUE072822T2 (hu) * 2013-12-20 2025-12-28 Intervet Int Bv Izoxazolin kompozíciók és azok felhasználása parazita fertõzések megelõzésében vagy kezelésében állatokban
CA2955975A1 (en) 2014-05-28 2015-12-03 Lunovus, Llc Ocular eyelid scrub composition for the treatment of demodex blepharitis
EP4512471A3 (en) 2014-06-19 2025-05-07 Attillaps Holdings Acetylcholinesterase inhibitors for treatment of dermatological conditions
TW201625564A (zh) 2014-07-23 2016-07-16 陶氏農業科學公司 具有某些殺蟲效用之分子及與其相關之中間物、組成物及方法（二）
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
US20170354593A1 (en) * 2014-11-03 2017-12-14 Zoetis Services Llc Palatable chewable veterinary composition
JP6706262B2 (ja) * 2014-12-22 2020-06-03 インターベット インターナショナル ベー． フェー． 毛包虫症治療のためのイソオキサゾリン化合物の使用
WO2016138049A1 (en) * 2015-02-24 2016-09-01 The Board Of Trustees Of The University Of Illinois Methods and compositions for treating dry eye disease and other eye disorders
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
US20160287566A1 (en) 2015-04-04 2016-10-06 Thomas Lynn Busby Anti-demodectic active agents and topical compositions for the treatment of demodicosis in humans and animals
WO2016207234A1 (en) * 2015-06-23 2016-12-29 Intervet International B.V. Isoxazoline solution containing vitamin e for use with sanitized drinking water
US20170024748A1 (en) 2015-07-22 2017-01-26 Patient Doctor Technologies, Inc. Guided discussion platform for multiple parties
CN108026063A (zh) * 2015-09-03 2018-05-11 阿格里麦蒂斯有限责任公司 作为杀虫剂的多杀菌素衍生物
NZ739853A (en) 2015-09-10 2018-11-30 Dow Agrosciences Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
CN108472312A (zh) 2015-09-28 2018-08-31 阿祖拉眼科有限公司 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
HRP20211979T1 (hr) 2016-04-06 2022-04-01 Boehringer Ingelheim Animal Health USA Inc. Postupak za pripravu enantiomerno obogaćenih spojeva izoksazolina – kristalnog toluen solvata (s)-afoksolanera
IL262180B2 (en) 2016-04-12 2025-12-01 Illustris Pharmaceuticals Inc Compositions for topical application of compounds
WO2017178416A1 (en) 2016-04-15 2017-10-19 Bayer Animal Health Gmbh Pyrazolopyrimidine derivatives
EP3532041A4 (en) 2016-10-31 2020-06-24 The Scripps Research Institute Methods and compositions for preventing vector-borne disease transmission
SI3723739T1 (sl) * 2017-12-15 2024-08-30 Tarsus Pharmaceuticals, Inc. Paraziticidni pripravki na osnovi izoksazolina in njihova uporaba za zdravljenje blefaritisa
JP7569781B2 (ja) 2018-07-27 2024-10-18 アペルタ バイオサイエンシズ，エルエルシー デモデックスにより誘発される眼の異常および顔面の異常を治療するためのスピノシン配合
EP3846786B1 (en) 2018-09-05 2024-11-13 Zoetis Services LLC Palatable antiparasitic formulations
KR20220054241A (ko) 2019-04-04 2022-05-02 타르서스 파마수티칼스, 아이엔씨. 벡터 매개 및 바이러스성 질환의 치료 또는 예방을 위한 전신 이속사졸린 구충제
US20220249445A1 (en) 2019-06-19 2022-08-11 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2020257663A1 (en) 2019-06-19 2020-12-24 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2021013825A1 (en) 2019-07-22 2021-01-28 Intervet International B.V. Soft chewable veterinary dosage form
JP2022545835A (ja) 2019-08-28 2022-10-31 ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー 甲状腺眼症の治療方法
WO2021243014A1 (en) 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions

Also Published As

Publication number Publication date
CN111655241A (zh) 2020-09-11
RU2020122841A (ru) 2022-01-18
IL275339B1 (en) 2023-11-01
US12364685B2 (en) 2025-07-22
CN119174758A (zh) 2024-12-24
JP2021506971A (ja) 2021-02-22
PL3723739T3 (pl) 2024-09-16
US10835517B2 (en) 2020-11-17
AU2018385766A1 (en) 2020-07-23
IL307992B2 (en) 2025-03-01
PT3723739T (pt) 2024-06-21
CA3085787A1 (en) 2019-06-20
US20230293496A1 (en) 2023-09-21
KR20200111177A (ko) 2020-09-28
AU2018385766B2 (en) 2022-12-01
KR20250059552A (ko) 2025-05-02
AU2023200843A1 (en) 2023-03-16
US20230301971A1 (en) 2023-09-28
US20210077466A1 (en) 2021-03-18
KR20250057155A (ko) 2025-04-28
CN119157876A (zh) 2024-12-20
ES2981130T3 (es) 2024-10-07
EP3723739A4 (en) 2022-04-20
US20190183862A1 (en) 2019-06-20
EP3723739A1 (en) 2020-10-21
EP3723739B1 (en) 2024-03-27
AU2023200843B2 (en) 2025-04-03
JP2024038449A (ja) 2024-03-19
US20220354829A1 (en) 2022-11-10
IL307992A (en) 2023-12-01
EP4397375A3 (en) 2024-09-25
US20210077465A1 (en) 2021-03-18
SI3723739T1 (sl) 2024-08-30
US20220054457A2 (en) 2022-02-24
CN111655241B (zh) 2024-10-15
US11752137B2 (en) 2023-09-12
US11690827B2 (en) 2023-07-04
US11197847B2 (en) 2021-12-14
US11690826B2 (en) 2023-07-04
IL275339A (en) 2020-07-30
US20250127762A1 (en) 2025-04-24
DK3723739T3 (da) 2024-06-17
US12213964B2 (en) 2025-02-04
MX2024000828A (es) 2024-02-08
US20250017908A1 (en) 2025-01-16
US20250312317A1 (en) 2025-10-09
FI3723739T3 (fi) 2024-06-19
KR20250065422A (ko) 2025-05-12
US20230190711A1 (en) 2023-06-22
US20250312318A1 (en) 2025-10-09
ZA202004155B (en) 2023-01-25
IL307992B1 (en) 2024-11-01
AU2025204628A1 (en) 2025-07-10
BR112020012018A2 (pt) 2020-11-24
US20210196689A1 (en) 2021-07-01
IL316352A (en) 2024-12-01
IL275339B2 (en) 2024-03-01
US12171750B2 (en) 2024-12-24
US20220354830A1 (en) 2022-11-10
NZ766141A (en) 2024-01-26
EP4397375A2 (en) 2024-07-10
HUE067461T2 (hu) 2024-10-28
US20220362218A1 (en) 2022-11-17
WO2019118928A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
PH12017502092A1 (en) Topical pharmaceutical compositions
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
MX346312B (es) Tratamientos oftalmicos.
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
AU2017261303A1 (en) Ophthalmic compositions
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX382949B (es) Formulaciones tópicas de detomidina.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
AU2020299145A8 (en) Compositions and methods for treating eye diseases
WO2016108572A3 (ko) 콜레스테롤 관련 질환의 예방 및 치료용 조성물
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
WO2014116015A3 (ko) 자죽염을 포함하는 알츠하이머병 예방용 조성물 및 자죽염의 제조방법
NZ766141B2 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis